Back to results

Massachusetts Institute of Technology

Understanding risk in a biopharmaceutical portfolio

Abstract

dc:description.abstract

Investors have difficulty funding the life sciences because of the high risks involved in research and development and commercialization of new products. Risk in the biopharmaceutical industry is the result of scientific, regulatory and economic uncertainty. The nature of the biopharmaceutical industry introduces many challenges. Each of these challenges incorporates a measure of risk into drug development. The level of understanding of technical success interdependencies has not been fully investigated. These interdependencies (correlations) could lead to an overall greater risk to the company's portfolio than previously expected. A better understanding of the risks that lead to success or failure in drug development might encourage more investment in the life sciences and specifically in the biopharmaceutical industry, and a greater awareness of the correlations between risks and products might lead to more informed decision making on a biopharmaceutical portfolio leading increased productivity. A dataset was collected from Thomson Reuters. The dataset is the oncology portfolio from a biopharmaceutical company, Genentech Inc. Logistic regression was used to determine if any of the defined variables contributed to the success or failure of the oncology products. The chi-square value was 7.738 with the degrees of freedom equal to 5 and with a p-value of 0.17. Therefore, none of the variables significantly contributed to the outcome. More research should be performed in this area in order to better understand the risk in a biopharmaceutical portfolio.

Degree

thesis:*
Department dc:contributor.department
Harvard University--MIT Division of Health Sciences and Technology.
Grantor dc:publisher
Massachusetts Institute of Technology
Year dc:date.issued
2011

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Wagner, Alice Elizabeth, 1980-
Advisor dc:contributor.advisor
  • Fiona Murray and Andrew W. Lo.

Subjects

dc:subject × 1

Rights

dc:rights
Statement dc:rights
  • M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Language dc:language.iso
eng

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1721.1/68469
OAI identifier oai:identifier
oai:dspace.mit.edu:1721.1/68469

Chain of custody

source
Harvested from
MIT
Base URL
dspace.mit.edu/oai/request
Last updated
2026-07-22
Source record
OAI-PMH GetRecord
citation

Wagner, Alice Elizabeth, 1980-. Understanding risk in a biopharmaceutical portfolio. Massachusetts Institute of Technology, 2011. http://hdl.handle.net/1721.1/68469